Outcomes of hematopoietic stem cell transplantation for Hurler's syndrome in Europe: A risk factor analysis for graft failure

Bone Marrow Transplantation

Volumn 40, Issue 3, 2007, Pages 225-233

  Boelens, J J ^a   Wynn, R F ^b   O'Meara, A ^c   Veys, P ^d   Bertrand, Y ^e   Souillet, G ^e   Wraith, J E ^b   Fischer, A ^f   Cavazzana Calvo, M ^f   Sykora, K W ^g   Sedlacek, P ^h   Rovelli, A ⁱ   Uiterwaal, C S P M ^j   Wulffraat, N ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b ROYAL MANCHESTER CHILDREN S HOSPITAL   (United Kingdom)

^c OUR LADY S CHILDREN S HOSPITAL   (Ireland)

^d GREAT ORMOND STREET HOSPITAL   (United Kingdom)

^e HÔPITAL DEBROUSSE   (France)

^f HÔPITAL NECKER ENFANTS MALADES   (France)

^g HANNOVER MEDICAL SCHOOL   (Germany)

^h UNIVERSITY HOSPITAL MOTOL   (Czech Republic)

ⁱ UNIVERSITY OF MILANO BICOCCA   (Italy)

^j UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; BUSULFAN; CYCLOPHOSPHAMIDE; CYCLOSPORIN; FLUDARABINE; MELPHALAN; METHOTREXATE; METHYLPREDNISOLONE; THIOTEPA; THYMOCYTE ANTIBODY; TREOSULFAN;

ARTICLE; CHILD; CONFIDENCE INTERVAL; CONTROLLED STUDY; DATA BASE; DRUG MEGADOSE; FEMALE; GRAFT FAILURE; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; HURLER SYNDROME; INFANT; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; REDUCED INTENSITY CONDITIONING; REGISTRATION; RISK FACTOR; SURVIVAL; T CELL DEPLETION; TREATMENT OUTCOME;

BUSULFAN; CHILD; CHILD, PRESCHOOL; DATABASES, FACTUAL; DISEASE-FREE SURVIVAL; EUROPE; FEMALE; GRAFT REJECTION; GRAFT SURVIVAL; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; INFANT; INFANT, NEWBORN; LOGISTIC MODELS; LYMPHOCYTE DEPLETION; MALE; MUCOPOLYSACCHARIDOSIS I; MYELOABLATIVE AGONISTS; RETROSPECTIVE STUDIES; RISK FACTORS; SURVIVAL RATE; TRANSPLANTATION CHIMERA; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS;

EID: 34547147899     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/sj.bmt.1705718     Document Type: Article

References (40)

1. Neufeld EF, Muenzer J. The mucopolysaccharidoses. In: Scriver CR, Beaudet AL, Sly WS, Valle D (eds). The Metabolic and Molecular Bases of Inherited Disease, 8th edn. McGraw-Hill: New York, 2001, pp 3421-3452.
2. Braunlin EA, Rose AG, Hopwood JJ, Candel RD, Krivit W. Coronary artery patency following long-term successful engraftment 14 years after bone marrow transplantation in the Hurler syndrome. Am J Cardiol 2001; 88: 1075-1088.
3. Hobbs JR, Hugh-Jones K, Barrett AJ, Byrom N, Chambers D, Henry K et al. Reversal of clinical features of Hurler's disease and biochemical improvement after treatment by bone-marrow transplantation. Lancet 1981; 2: 709-712.
4. Summers CG, Purple RL, Krivit W, Pineda R, Copland GT, Ramsay NKC et al. Ocular changes in the mucopolysaccharidoses after bone-marrow transplantation. Ophthalmology 1989; 96 977-984.
5. Vinallonga X, Sanz N, Balaguer A, Miro L, Ortega JJ, Casaldaliga J. Hypertrophic cardiomyopathy in mucopolysaccharidoses - regression after bone-marrow transplantation. Pediatr Cardiol 1992; 13: 107-109.
6. Krivit W, Henslee-Downey J, Klemperer M. Survival in Hurler's disease following bone marrow transplantation in 84 patients. Bone Marrow Transplant 1995; 15: S182-S185.
7. Shapiro EG, Lockman LA, Balthazor M, Krivit W. Neuropsychological outcomes of several storage diseases with and without bone-marrow transplantation. J Inherited Metab Dis 1995; 18: 413-429.
8. Vellodi A, Young EP, Cooper A, Wraith JE, Winchester B, Meaney C et al. Bone marrow transplantation for mucopolysaccharidosis type I: experience of two British centres. Arch Dis Childhood 1997; 76 92-99.
9. Peters C, Balthazor M, Shapiro EG, King RJ, Kollman C, Hegland JD et al. Outcome of unrelated donor bone marrow transplantation in 40 children with Hurler syndrome. Blood 1996; 87: 4894-4902.
10. Peters C, Shapiro EG, Anderson J, Henslee-Downey PJ, Klemperer MR, Cowan MJ et al. Hurler syndrome: II. Outcome of HLA genotypically identical sibling and HLA-haploidentical related donor bone marrow transplantation in fifty-four children. Blood 1998; 91: 2601-2608.
11. Souillet G, Guffon N, Maire I, Pujol M, Taylor P, Sevin F et al. Outcome of 27 patients with Hurler's syndrome transplanted from either related or unrelated haematopoietic stem cell sources. Bone Marrow Transplant 2003; 31: 1105-1117.
12. Staba SL, Escolar ML, Poe M, Kim Y, Martin PL, Szabolcs P et al. Cord-blood transplants from unrelated donors in patients with Hurler's syndrome. N Engl J Med 2004; 350: 1960-1969.
13. Kurtzberg J, Krivit W. Cord blood transplantation for lysosomal storage diseases demonstrates the potential of cord blood cells for future cellular therapies. Blood (ASH meeting) 2004; 3602 (abstract).
14. Peters C, Shapiro EG, Krivit W. Hurler syndrome: Past, present, and future. J Pedlatr 1998; 133: 7-9.
15. Orchard PJ, Grewal S, Milla C, Braunlin EA, Defor T, Panoskaltsis-Mortari A et al. Pulmonary risk factors in allogeneic transplantation for Hurler syndrome. Blood 2004; 104: 592A.
16. Glucksberg H, Storb R, Fefer A, Buckner CD, Neiman PE, Clift RA et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors. Transplantation 1974; 18: 295-304.
17. Shulman HM, Sullivan KM, Weiden PL, McDonald GB, Striker GE, Sale GE et al. Chronic graft-versus-host syndrome in man: A long-term clinicopathologic study of 20 Seattle patients. Am J Med 1980; 69: 204-217.
18. Reiss U, Cowan M, McMillan A, Horn B. Hepatic venoocclusive disease in blood and bone marrow transplantation in children and young adults: incidence, risk factors, and outcome in a cohort of 241 patients. J Pediatr Hematol Oncol 2002; 24: 746-750.
19. Martin P, Carter S, Kernan N, Sahdev I, Wall D, Pietryga D et al. Results of the Cord Blood Transplantation Study (COBLT): Outcomes of unrelated donor umbilical cord blood transplantation in pediatric patients with lysosomal and peroxisomal storage diseases. Biol Blood Marrow Transplant 2006; 12: 184-194.
20. Escolar ML, Poe MD, Provenzale JM, Richards KC, Allison J, Wood S et al. Transplantation of umbilical-cord blood in babies with infantile Krabbe's disease. N Engl J Med 2005; 352: 2069-2081.
21. Guffon N, Fouilhoux A, Bertrand Y, Thomalla M. Longitudinal neurocognitive follow-up of 26 MPSI patients with human stem cell transplantation or with enzyme replacement therapy. Ninth International Symposium on Mucopolysaccharide and Related Diseases, Venice, 2006, p 166.
22. Rubinstein P, Dobrila L, Rosenfield RE. Processing and cryopreservation of placental/umbilical cord blood for unrelated bone marrow reconstitution. Proc Nod Acad Sci USA 1995; 92: 10119-10122.
23. Kogler G, Sensken S, Airey JA, Trapp T, Muschen M, Feldhahn N et al. A new human somatic stem cell from placental cord blood with intrinsic pluripotent differentiation potential. J Exp Med 2004; 200: 123-135.
24. Chen N, Hudson JE, Walczak P, Misiuta I, Garbuzova-Davis S, Jiang L et al. Human umbilical cord blood progenitors: The potential of these hematopoietic cells to become neural. Stem Cells 2005; 23: 1560-1570.
25. Meier C, Middelanis J, Wasielewski B, Neuhoff S, Roth-Haerer A, Gantert M et al. Spastic paresis after perinatal brain damage in rats is reduced by human cord blood mononuclear cells. Pediatr Res 2006; 59: 244-249.
26. Le Blanc K, Ringden O. Immunobiology of human mesenchymal stem cells and future use in hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2005; 11: 321-334.
27. Ryan JM, Barry FP, Murphy JM, Mahon BP. Mesenchymal stem cells avoid allogeneic rejection. J Inflamm (London) 2005; 2: 8.
28. Ballen KK. New trends in umbilical cord blood transplantation. Blood 2005; 105: 3786-3792.
29. Gluckman E, Rocha V, Arcese W, Michel G, Sanz G, Chan KW et al. Factors associated with outcomes of unrelated cord blood transplant: guidelines for donor choice. Exp Hematol 2004; 32: 397-407.
30. Wagner JE, Barker IN, Defor TE, Baker KS, Blazar BR, Eide C et al. Transplantation of unrelated donor umbilical cord blood in 102 patients with malignant and nonmalignant diseases: Influence of CD34 cell dose and HLA disparity on treatment-related mortality and survival. Blood 2002; 100: 1611-1618.
31. Chao NJ, Emerson SG, Weinberg KI. Stem cell transplantation (cord blood transplants). Hematol ASH Educ. Program 2004, 354-371.
32. Bolinger AM, Zangwill AB, Slattery JT, Glidden D, DeSantes K, Heyn L et al. An evaluation of engraftment, toxicity and busulfan concentration in children receiving bone marrow transplantation for leukemia or genetic disease. Bone Marrow Transplant 2000; 25 925-930.
33. Zwaveling J, Bredius RGM, Cremers SCLM, Ball LM, Lankester AC, Teepe-Twiss IM et al. Intravenous busulfan in children prior to stem cell transplantation: Study of charmacokinetics in association with early clinical outcome and toxicity. Bone Marrow Transplant 2005; 35: 17-23.
34. Vassal G, Koscielny S, Challine D, ValteauCouanet D, Boland I, Deroussent A et al. Busulfan disposition and hepatic veno-occlusive disease in children undergoing bone marrow transplantation. Cancer Chernother Pharmacol 1996; 37: 247-253.
35. Bolinger AM, Zangwill AB, Slattery JT, DeSantes K, Heyn L, Risler LJ et al. Target dose adjustment of busulfan using pharmacokinetic parameters in pediatric patients undergoing bone marrow transplantation for malignancy or inborn errors. Blood 1997; 90: 1665.
36. Baxter MA, Wynn RF, Schyma L, Holmes DK, Wraith JE, Fairbairn LJ et al. Marrow stromal cells from patients affected by MPS I differentially support haematopoietic progenitor cell development. J Inherited Metab Dis 2005; 28: 1045-1053.
37. Resnick IB, Shapira MY, Slavin S. Nonmyeloablative stem cell transplantation and cell therapy for malignant and non-malignant diseases. Transplant Immunol 2005; 14: 207-219.
38. Slavin S, Aker M, Shapira MY, Resnick I, Bitan M, Or R. Reduced-intensity conditioning for the treatment of malignant and life-threatening non-malignant disorders. Clin Transplant 2003; 26: 275-282.
39. Jacobsohn DA, Duerst R, Tse W, Kletzel M. Reduced intensity haemopoietic stem-cell transplantation for treatment of non-malignant diseases in children. Lancet 2004; 364: 156-162.
40. Grewal SS, Krivit W, Defor TE, Shapiro EG, Orchard PJ, Abel SL et al. Outcome of second hematopoietic cell transplantation in Hurler syndrome. Bone Marrow Transplant 2002; 29: 491-496.